Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Magnetic helmet shows promise for long COVID brain fog in small study

NCT ID NCT06739668

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a low-level magnetic therapy device, used at home, is safe and practical for people with Long COVID who have memory and thinking problems. Thirty adults with persistent cognitive issues after COVID-19 used the device daily for 4 weeks, then were followed for another month. The main goal was to see if people could use it easily and comfortably, not to prove it works, but results will help design larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Dec 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * English Speaking * SARS CoV-2 infection as documented by laboratory nucleic acid amplification test or antibody test ≥ 6 months from screening or signed attestation of positive test result * Experiencing PASC symptoms ≥ 6 months * Objective cognitive impairment on neuropsychological measures (as defined by a z-score ≥1 standard deviation below the normative mean) in executive functioning * Individuals of childbearing age agreeing to use a highly effective form of birth control Exclusion Criteria: * History of cognitive dysfunction present prior to SARS CoV-2 infection * Febrile (\> 99 F) at the time of the enrollment visit * Enrollment in another interventional clinical trial in the last 90 days or during the study period * Recent SARS CoV-2 reinfection in the last 30 days or during the study period * Recent SARS CoV-2 vaccination in the last 30 days or plans to be vaccinated during the 8 week study period * Currently taking immunomodulatory medication on an ongoing basis (NSAIDs, corticosteroids, cytokine antagonists, IVIG) * History of bipolar disorder, psychotic disorder, substance use disorder * Change in anti-depressant or other psychoactive medication or dose in the last 90 days * Cranially implanted devices or metal * Any serious unstable medical or neurologic condition * History of severe head injury (as defined by loss of consciousness for ≥30 minutes) or stroke in the past 12 months * Pregnant or plan to become pregnant during the study as indicated by positive pregnancy test * Serious immune/autoimmune diagnoses prior to SARS-CoV-2 infection * ME/CFS diagnosis prior to first SARS-CoV-2 infection * Existing diagnosis of Post-treatment Lyme Disease Syndrome * Inability to achieve appropriate positioning of the study device on the head

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.